HJF Receives Patent for Potential Treatment for Nerve Agent Exposure

HJF Receives Patent for Potential Treatment for Nerve Agent Exposure
News provided by
Share this article
Share this article
BETHESDA, Md., May 11, 2021 /PRNewswire/ -- The Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc. (HJF) received notice of allowance for a patent from the United States Patent Office (USPO) for a medical countermeasure to organophosphate (OP) nerve agent exposure. Among OP nerve agents is the deadly chemical weapon, Sarin. Led by Maria F. Braga, DDS, PhD, a professor of Anatomy, Physiology and Genetics, and Psychiatry in the in the School of Medicine at the Uniformed Services University of the Health Sciences (USU), researchers identified a neuroprotective combination therapy that is effective against OP exposure. The therapy was shown to be effective even with delayed use following nerve agent exposure. This innovation was patented by the USU/HJF Joint Office of Technology Transfer.

Related Keywords

Eli Lilly ,Henrym Jackson Foundation ,Technologies Department ,National Institute Of Health ,Department Of Defense ,Defense Threat Reduction Agency Chemical ,Defense Threat Reduction Agency ,Biological Technologies Department ,National Institute ,Military Medicine ,எலி லில்லி ,தொழில்நுட்பங்கள் துறை ,தேசிய நிறுவனம் ஆஃப் ஆரோக்கியம் ,துறை ஆஃப் பாதுகாப்பு ,உயிரியல் தொழில்நுட்பங்கள் துறை ,தேசிய நிறுவனம் ,இராணுவம் மருந்து ,